BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

VeroScience 

1334 Main Road

Tiverton  Rhode Island  02878  U.S.A.
Phone: 401-816-0525 Fax: 401-816-0524


SEARCH JOBS


Industry
Biotechnology

Segment
Start Up





 Company News
Santarus Inc. (SNTS) and VeroScience Announce CYCLOSET (bromocriptine mesylate) Data Presentations at the American Diabetes Association Meeting 6/21/2013 7:00:01 AM    More...
Santarus Inc. (SNTS) and VeroScience Announce Publication of American Association of Clinical Endocrinologists Expert Panel Recommendations for CYCLOSET® (bromocriptine mesylate) for the Management of Type 2 Diabetes 3/6/2013 9:57:25 AM    More...
Santarus Inc. (SNTS) and VeroScience Announce Publication of Positive Data From Pivotal CYCLOSET® (bromocriptine mesylate) Efficacy Study 1/23/2013 9:41:13 AM    More...
Santarus Inc. (SNTS) Buys License To Make Diabetes Drug For $5 Mln From S2 Biosciences Inc. And VeroScience 9/9/2010 6:53:42 AM    More...
VeroScience Announces FDA Approval of Cycloset for Treatment of Type 2 Diabetes 5/6/2009 8:33:07 AM    More...
VeroScience Release: Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset(TM) in Patients with Type 2 Diabetes 6/25/2007 10:32:20 AM    More...
VeroScience Late-Breaking Abstract on Cycloset(TM) (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions 6/18/2007 11:22:23 AM    More...

//-->